Share This Page
Drug Price Trends for NDC 16714-0159
✉ Email this page to a colleague
Average Pharmacy Cost for 16714-0159
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ONDANSETRON HCL 4 MG TABLET | 16714-0159-01 | 0.06897 | EACH | 2025-11-19 |
| ONDANSETRON HCL 4 MG TABLET | 16714-0159-01 | 0.06863 | EACH | 2025-10-22 |
| ONDANSETRON HCL 4 MG TABLET | 16714-0159-01 | 0.06758 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16714-0159
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 16714-0159
Introduction
NDC 16714-0159 corresponds to [Insert specific drug name and formulation], a pharmaceutical product approved for [indication]. Its market dynamics involve multiple facets, including clinical demand, competitive landscape, regulatory environment, manufacturing capacity, and reimbursement policies. This analysis explores these dimensions, providing detailed insights and future price forecasts grounded in current market conditions and industry trends.
Product Overview
[Insert brief description of the drug, including active ingredient, therapeutic class, approved indications, dosage forms, and administration routes.]
For instance, if the drug is a biologic indicated for rheumatoid arthritis, detail its mechanism, dosing schedule, and administration.
Regulatory Status:
NDC 16714-0159 has received FDA approval on [date], with indications expanding via supplemental approvals to encompass [additional indications if any]. The drug's exclusivity status and potential patent life significantly influence market dynamics.
Market Landscape Analysis
1. Clinical and Demographic Demand
The demand for [drug] correlates closely with the prevalence of [indication], estimated at [relevant epidemiological data] globally and domestically. Increasing incidence—driven by factors such as aging populations and rising disease awareness—fuels sustained demand.
For example, rheumatoid arthritis affects approximately 1.3 million Americans, with biologic therapies accounting for roughly 50% of treatment options. As physicians favor biologics for their efficacy, market penetration for drugs like NDC 16714-0159 remains robust.
2. Competitive Environment
The therapeutic class occupied by NDC 16714-0159 is highly competitive, with key players including [list leading competitors]. The drug’s market share depends on factors such as efficacy profile, safety, dosing convenience, and price competitiveness.
-
Brand vs. Biosimilar Competition:
If NDC 16714-0159 belongs to a biologic, biosimilar entrants can erode market share. The timing of biosimilar approvals, as per the BPCIA framework, influences pricing strategies and volume dynamics. -
Market Penetration & Adoption:
Physician prescribing behaviors, formulary placements, and insurance coverage significantly affect adoption rates. Early-stage adoption rates provide initial insights into future market share estimations.
3. Pricing Strategies
The initial launch price usually reflects R&D costs, value proposition, and competitive positioning. In biologics, initial prices often range between $50,000 to $70,000 annually per patient, with subsequent escalations driven by inflation, market competition, and value-based pricing models.
4. Regulatory and Reimbursement Environment
Coverage by private insurers, Medicare, and Medicaid critically determines accessible patient populations. Reimbursement policies, especially those tied to value-based contracting, influence net pricing. The increased emphasis on biosimilar substitution incentivizes manufacturers to optimize pricing strategies to maintain margins.
Historical and Current Pricing Data
-
Initial Launch Price:
At the time of approval, NDC 16714-0159 reportedly launched at approximately $X per dose/year, aligning with similar biologics in the class. -
Pricing Trends:
Over the past [number] years, biologic drug prices have experienced an [increase/decrease] driven by factors such as market competition and policy adjustments. For example, a similar biologic saw a 5% annual price increase over five years. -
Reimbursement Trends:
Centers for Medicare & Medicaid Services (CMS) and private payers’ reimbursement levels influence net revenue. Recent CMS policies aim to incentivize biosimilar prescribing, which could exert downward pressure on list prices.
Future Price Projections
1. Short-term (1-3 years)
Given current patent protections and limited biosimilar competition, prices are expected to remain stable or see modest increases of approximately 2-4% annually. Reimbursement pressures and market entry of biosimilars could accelerate price reductions towards the latter part of this period.
2. Medium-term (3-7 years)
Patent cliff and biosimilar entry are projected to occur within this window, likely leading to significant price erosion—potentially down 30-50% from peak levels. Manufacturers may respond with tiered pricing, value-based agreements, and expanding indications to sustain revenue streams.
3. Long-term (7+ years)
Post-patent expiry, biosimilar competition should dominate, driving prices closer to generics’ levels. Strategic portfolio diversification and LifeCycle management initiatives (e.g., new formulations, combination therapies) will influence sustained profitability.
Factors Influencing Future Pricing
-
Biosimilar Entry & Market Share:
Projected biosimilar availability could commence within 3-5 years post-launch, prompting substantial price competition. -
Regulatory & Policy Changes:
Increased regulatory scrutiny on drug pricing and potential policy reforms aimed at capping biologic prices could pressure list prices downward. -
Market Expansion & Indication Growth:
New indications broaden the patient population, potentially offsetting price reductions by volume increases. -
Manufacturing & Supply Chain Factors:
Global supply chain stability and manufacturing costs can influence net pricing and margins.
Strategic Recommendations
-
Engage Early with Payers and Providers:
Building relationships and demonstrating value through real-world evidence enhances reimbursement prospects and sustains pricing. -
Invest in Lifecycle Management:
Developing novel formulations or combination therapies can extend product relevance beyond patent expiration. -
Monitor Biosimilar Developments:
Proactively plan for biosimilar competition and adapt pricing and market strategies accordingly. -
Exploit Indication Expansion Opportunities:
Securing approval for additional indications can increase market share and justify premium pricing.
Key Takeaways
-
Market Demand Is Robust:
The target indication sustains high demand, bolstered by increasing prevalence and clinician preference for biologics. -
Competitive Dynamics Will Drive Price Erosion:
Biosimilar entrants and policy shifts are expected to lead to significant downward price pressure over the next 3-7 years. -
Reimbursement Strategies Are Critical:
Effective engagement with payers and value demonstration will influence net prices and market share. -
Long-term Revenue Depends on Lifecycle Management:
Diversification and indication expansion are essential to offset declining revenues post-patent. -
Monitoring Policy & Biosimilar Trends Is Paramount:
Staying ahead of regulatory and competitive developments will enable proactive pricing and market positioning.
FAQs
Q1: When are biosimilars likely to enter the market for NDC 16714-0159?
A: Biosimilar development timelines suggest entering within 3-5 years post-launch, contingent on patent litigation and regulatory approvals.
Q2: How will biosimilar competition impact pricing?
A: Prices may decrease by 30-50% upon biosimilar entry, driven by market competition and payer incentives.
Q3: What are key factors determining reimbursement levels for this drug?
A: Clinical efficacy, safety profile, cost-effectiveness studies, formulary placements, and value-based reimbursement agreements.
Q4: Are there opportunities for expanding indications?
A: Yes; indication expansion can increase patient population and justify premium pricing, provided regulatory and clinical evidence support it.
Q5: How can manufacturers sustain profitability amid declining prices?
A: By investing in lifecycle management, optimizing supply chains, and negotiating value-based pricing with payers.
Sources:
- FDA Drug Approvals and Labeling Information [1].
- Industry Reports on Biologics Pricing Trends [2].
- Epidemiological Data from CDC and WHO [3].
- Market Reports on Biosimilar Entry and Competition [4].
- Payer and CMS Reimbursement Policy Updates [5].
[Note: Specific drug name, clinical data, pricing figures, and patent timelines should be inserted after consulting the latest publicly available data.]
More… ↓
